The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
张欢馨
v0id
woshi123
cdercder
yzy
Kao
22336
云城
yjh123
科研狗
乐空思
丰富语蕊
XLL小绿绿
GingerF
lixinglei
Oracle
aaaa
xing_xing
OK
丁浩伦
皖公网安备34019202002308
